10-QPeriod: Q1 FY2023

IDEXX LABORATORIES INC /DE Quarterly Report for Q1 Ended Mar 31, 2023

Filed May 2, 2023For Securities:IDXX

Summary

IDEXX Laboratories, Inc. (IDXX) reported solid financial results for the first quarter of 2023, demonstrating continued growth driven by its Companion Animal Group (CAG) segment. Total revenue increased by 7.6% year-over-year to $900.2 million, with organic revenue growth of 9.8%, reflecting strong performance in recurring revenue, price increases, and software/service offerings. Despite some headwinds in the LPD and Other segments, the company's overall profitability improved, with a 12.9% increase in income from operations to $280.4 million. The company also showed progress in managing its financial resources, evidenced by a significant increase in operating cash flow and a reduction in credit facility borrowings. While facing inflationary pressures impacting cost of revenue and operating expenses, IDEXX maintained its focus on strategic investments in growth initiatives, particularly within its core CAG segment. The company's financial position remains strong, with ample liquidity and a conservative leverage ratio, positioning it well for future growth and resilience.

Financial Highlights

53 data points
Beta

Revenue

$900.20M

60.3% Gross Margin

Net Income

$214.05M

23.8% Net Margin

EPS (Diluted)

$2.55

Total Assets

$2.81B

Cash & Equivalents

$111.37M

Free Cash Flow

$144.40M

Financial Statements
Beta
Revenue$900.20M
Cost of Revenue$357.22M
Gross Profit$542.97M
R&D Expenses$44.67M
Operating Income$280.40M
Interest Expense$13.13M
Net Income$214.05M
EPS (Basic)$2.58
EPS (Diluted)$2.55
Shares Outstanding (Basic)82.99M
Shares Outstanding (Diluted)83.96M

Key Highlights

  • 1Total revenue increased by 7.6% to $900.2 million, driven by organic growth of 9.8%.
  • 2Companion Animal Group (CAG) revenue grew 8.7% to $827.3 million, with CAG Diagnostics recurring revenue up 9.3%.
  • 3Income from operations rose 12.9% to $280.4 million, indicating improved profitability.
  • 4Gross profit margin improved by 70 basis points to 60.3%, despite inflationary cost pressures.
  • 5Net cash provided by operating activities significantly increased by 60.3% to $183.9 million.
  • 6The company reduced outstanding borrowings under its Credit Facility by $147.5 million during the quarter.
  • 7Effective tax rate was 20.0%, slightly up from 19.7% in the prior year period.

Frequently Asked Questions

The primary driver of IDEXX's revenue growth was its Companion Animal Group (CAG) segment, particularly its CAG Diagnostics recurring revenue. This growth was fueled by higher realized prices globally and increased demand in the U.S. for companion animal diagnostics. Growth in subscription-based veterinary software and diagnostic imaging services also contributed positively.

IDEXX improved its gross profit margin by 70 basis points to 60.3%. This was achieved through higher realized prices, improved software services margins, productivity initiatives in its reference laboratories, and a favorable product mix. While facing higher product, labor, and distribution costs due to inflation, the company effectively managed these pressures to drive overall profit growth.

IDEXX maintains a strong liquidity position, with $111.4 million in cash and cash equivalents as of March 31, 2023. The company significantly reduced its outstanding borrowings under its Credit Facility by $147.5 million during the quarter, bringing the total outstanding to $431.5 million. The company has substantial remaining borrowing availability of $817.0 million under its $1.25 billion Credit Facility, ensuring ample resources for operations and growth initiatives. The company remains in compliance with its financial covenants.

Yes, the Livestock, Poultry and Dairy (LPD) segment experienced a revenue decrease of 5.4%, primarily due to lower herd health screening volumes in China and reduced volumes in its food safety product distribution business in Brazil. The 'Other' segment also saw a significant revenue decline of 40.6%, mainly due to lower sales of OPTI COVID-19 PCR testing products and services.